Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Mimedx Group Inc (MDXG)
Mimedx Group Inc (MDXG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 915,887
  • Shares Outstanding, K 116,377
  • Annual Sales, $ 267,840 K
  • Annual Income, $ -30,200 K
  • 60-Month Beta 1.66
  • Price/Sales 3.42
  • Price/Cash Flow N/A
  • Price/Book 699.14
Trade MDXG with:

Options Overview Details

View History
  • Implied Volatility 41.84% ( -1.63%)
  • Historical Volatility 50.55%
  • IV Percentile 13%
  • IV Rank 13.18%
  • IV High 246.89% on 02/02/23
  • IV Low 10.73% on 03/30/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 28
  • Volume Avg (30-Day) 113
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 5,731
  • Open Int (30-Day) 5,569

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate 0.08
  • Number of Estimates 3
  • High Estimate 0.08
  • Low Estimate 0.07
  • Prior Year -0.02
  • Growth Rate Est. (year over year) +500.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.57 +42.37%
on 11/10/23
8.20 -3.29%
on 12/04/23
+1.44 (+22.19%)
since 11/07/23
3-Month
5.57 +42.37%
on 11/10/23
8.28 -4.28%
on 09/12/23
+0.28 (+3.66%)
since 09/07/23
52-Week
2.43 +226.34%
on 12/20/22
8.60 -7.79%
on 08/02/23
+4.90 (+161.72%)
since 12/07/22

Most Recent Stories

More News
3 Medical Stocks Diagnosing Weekly Profit Potential

The healthcare industry is experiencing rapid transformation and is well-positioned to thrive due to the rising demand for high-quality healthcare and medical device innovation. Hence, fundamentally strong...

CAH : 106.38 (+0.48%)
MDXG : 7.93 (+0.76%)
NATR : 16.92 (+0.53%)
3 Medical Stocks Elevating Investors' Profit Potential

Within the rapidly evolving healthcare landscape, opportunities arise from operational improvements, making the sector poised for significant expansion. Hence, fundamentally strong medical stocks Cardinal...

CAH : 106.38 (+0.48%)
FSNUY : 7.6500 (-1.03%)
MDXG : 7.93 (+0.76%)
Henry Schein (HSIC) Q3 Earnings Analysis: A Medical Stock to Watch?

Henry Schein (HSIC) posted solid third-quarter 2023 sales growth and non-GAAP EPS growth despite continued lower sales of PPE products and COVID-19 test kits. In addition, the company’s long-term outlook...

FONR : 19.80 (+1.69%)
HSIC : 71.54 (+1.30%)
MDXG : 7.93 (+0.76%)
OCPNY : 18.0000 (-1.37%)
Assessing Alcon Inc.’s (ALC) Post-Earnings Prospects: Is It Time to Invest, Hold, or Let Go?

Is Swiss eye care leader Alcon Inc. (ALC) a buy, hold, or sell after its third-quarter earnings release yesterday? Let’s look at its financial metrics to gauge its prospects… Geneva, Switzerland-based...

ALC : 71.90 (-0.04%)
FONR : 19.80 (+1.69%)
MDXG : 7.93 (+0.76%)
VREX : 19.38 (+4.25%)
Becton Dickinson & Co. (BDX) Earnings Moves: A Buy or Sell for Investors?

Becton Dickinson & Co. (BDX) is expected to report steady growth for its fiscal fourth quarter ended September 2023, scheduled to be released on November 9. While the stock is witnessing weakness over...

BDX : 233.54 (+0.04%)
ELMD : 10.32 (+0.19%)
FONR : 19.80 (+1.69%)
MDXG : 7.93 (+0.76%)
Are These 3 Medical Stocks a Safe Investment?

The future of the medical devices and equipment industry looks buoyant, given rising chronic conditions and the adoption of advanced technology. Given this backdrop, would it be prudent for investors to...

HAE : 83.26 (+1.38%)
MDXG : 7.93 (+0.76%)
TRUMY : 33.0800 (+3.09%)
MiMedx Group (NASDAQ: MDXG) Reports Q1 2023 Financial Results Showing 21.7% Sales Growth

MiMedx Group, Inc. (NASDAQ: MDXG) is engaged as a biotechnology company that is focused as a placental biologics developer to

MDXG : 7.93 (+0.76%)
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END

VCEL : 34.24 (+1.84%)
OCEL : 1.7000 (unch)
BRTX : 1.7900 (-1.07%)
MDXG : 7.93 (+0.76%)
NNVC : 1.1550 (-1.28%)
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

/PRNewswire/ -- Chronic obstructive pulmonary disease is a chronic lung disease that prevents airflow from the lungs. The rising incidence of COPD is one...

OCEL : 1.7000 (unch)
BRTX : 1.7900 (-1.07%)
MDXG : 7.93 (+0.76%)
NNVC : 1.1550 (-1.28%)
VCEL : 34.24 (+1.84%)
MIMEDX to Present at the Canaccord Genuity 42nd Annual Growth Conference

MARIETTA, Ga., Aug. 04, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics...

MDXG : 7.93 (+0.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. `Innovations in Regenerative Biomaterials` is the framework behind their mission to give physicians products and tissues to help the...

See More

Key Turning Points

3rd Resistance Point 8.38
2nd Resistance Point 8.23
1st Resistance Point 8.08
Last Price 7.93
1st Support Level 7.78
2nd Support Level 7.63
3rd Support Level 7.48

See More

52-Week High 8.60
Last Price 7.93
Fibonacci 61.8% 6.24
Fibonacci 50% 5.52
Fibonacci 38.2% 4.79
52-Week Low 2.43

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar